natgillin/translations-raw huggingface dataset:
Baseline score, mean (SD) 17.6 (28.62) 19.2 (32.68) 15.2 (28.86) 15.9 (27.37) 
17,6 (28,62) 19,2 (32,68) 15,2 (28,86) 15,9 (27,37) ni podatka ni podatka
The grey syringe plunger should be pushed all the way to the end of the syringe. 
Sivi bat brizge morate potisniti vse do konca brizge.
Keep holding the clear base firmly against your skin. 
Še naprej trdno držite prozorno podnožje na koži.
From Week 12, you will use an 80 mg dose (one injection) every 4 weeks. 
Od 12. tedna dalje boste uporabljali odmerek 80 mg (ena injekcija) vsake 4 tedne.
Etanercept 50 mg twice weekly (N = 358) 
etanercept 50 mg dvakrat na teden (N = 358)
Leave the needle cap on the syringe until you are ready to inject. 
Pokrovčka igle ne snemajte z brizge, dokler niste pripravljeni na injiciranje.
A. It is normal to sometimes have air bubbles in the syringe. 
O: Občasni zračni mehurčki v brizgi so normalen pojav.
b p<0.01; c p<0.001 compared with placebo. 
b p<0,01; c p<0,001 v primerjavi s placebom.
• The grey syringe plunger should be pushed all the way to the end of the syringe. 
• Sivi bat brizge morate potisniti vse do konca brizge.
Taltz is used to treat a skin condition called “plaque psoriasis” in adults with moderate to severe disease. 
Zdravilo Taltz se uporablja za zdravljenje kožne bolezni, imenovane "psoriaza s plaki" pri odraslih z zmerno do hudo boleznijo.
However, ixekizumab is excreted at low levels in the milk of cynomolgus monkeys. 
Iksekizumab pa se v majhnih količinah izloča v mleko opic vrste javanski makak (cynomolgus).
For psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis, the recommended dosing regimen is the same as for plaque psoriasis. 
Za bolnike s psoriatičnim artritisom, ki imajo sočasno zmerno do hudo psoriazo s plaki, je priporočeni režim odmerjanja enak kot za bolnike s psoriazo s plaki.
Each syringe contains one dose of Taltz (80 mg). 
Ena brizga vsebuje en odmerek zdravila Taltz (80 mg).
Taltz has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Taltz nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Etanercept 50 mg twice weekly (N = 382) 
etanercept 50 mg dvakrat na teden (N = 382)
Taltz was associated with a fast onset of efficacy with > 50 % reduction in mean PASI by Week 2 (Figure 1). 
Zdravilo Taltz je bilo povezano s hitrim nastopom učinkovitosti s > 50 % znižanjem povprečne ocene
Abbreviations: N = number of patients in the intent-to-treat population Note: patients with missing data were counted as non-responders. 
Opomba: bolnike z manjkajočimi podatki smo šteli kot bolnike, ki se niso odzvali.
Plaque psoriasis - The first dose is 160 mg (two 80 mg injections) by subcutaneous injection. 
Psoriaza s plaki - Prvi odmerek je 160 mg (dve injekciji po 80 mg) s subkutano injekcijo.
Taltz is used to treat a condition called “psoriatic arthritis”, an inflammatory disease of the joints, often accompanied by psoriasis. 
Zdravilo Taltz se uporablja za zdravljenje bolezni, imenovane "psoriatični artritis", vnetne bolezni sklepov, ki jo pogosto spremlja psoriaza.
At Week 12, significantly more subjects in the TALTZ group than placebo group achieved a sPGA of Genitalia 0/1 and a sPGA 0/1 independent of baseline BSA (baseline BSA 1% - <10% resp. ≥10%: sPGA of Genitalia ‘'0” or “1”: Taltz 71%, resp. 75%; placebo: 0%, resp. 13%). 
V 12. tednu je v skupini z zdravilom TALTZ bistveno več bolnikov doseglo oceno sPGA za genitalije 0/1 in sPGA 0/1 v primerjavi s skupino s placebom, neodvisno od izhodiščne BSA (izhodiščna BSA 1 % - < 10 % oziroma ≥ 10 %: sPGA za genitalije »0« ali »1«: Taltz 71 %, oziroma 75 %; placebo: 0 %, oziroma 13 %).
The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation. 
Večina okužb ni bila resnih in je bila blage do zmerne jakosti.
You and your doctor should decide if you will breast-feed or use Taltz. 
Skupaj se bosta odločila, ali boste dojili ali pa jemali zdravilo Taltz.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands. 
Imetnik dovoljenja za promet z zdravilom Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
- After the first dose you will use an 80 mg dose (one injection) every 4 weeks. 
- Po prvem odmerku boste uporabili odmerek 80 mg (ena injekcija) vsake 4 tedne.
Patients on Taltz Q2W or Q4W remained on their originally assigned dose of Taltz. 
Bolniki, ki so prejemali Taltz Q2W ali Q4W, so obdržali svoj izvorno dodeljeni odmerek zdravila Taltz.
sPGA of Genitalia “0” or “1” sPGA “0” or “1” DLQI 0,1b 
Ocena sPGA za genitalije »0« ali »1« sPGA »0« ali »1«
Mean (SD) Cmax,ss, and Ctrough,ss estimates are 14.6 (6.04) µg/ml, and 1.87 (1.30) µg/ml. 
trough,ss so 14,6 (6,04) µg/ml in 1,87 (1,30) µg/ml.
In patients with ≥3% BSA, the improvement in skin clearance at Week 12 as measured by 75% improvement in Psoriasis Area Severity Index (PASI 75), was 67% (94/141) for those treated with the Q4W dosing regimen, and 9% (12/134) for those treated with placebo (p<0.001). 
Pri bolnikih s ≥ 3 % BSA, je znašalo izboljšanje v čistosti kože v 12. tednu, merjeno s 75-odstotnim izboljšanjem indeksa PASI (PASI 75), 67 % (94/141) pri bolnikih, zdravljenih z režimom Q4W, in 9 % (12/134) pri bolnikih, ki so prejemali placebo (p<0,001).
This medicine contains less than 1 mmol sodium (23 mg) per 80 mg dose, i.e., essentially “sodiumfree”. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na 80-miligramski odmerek, torej je v bistvu »brez natrija«.
Results from a drug-drug interaction study in patients with moderate-to-severe psoriasis determined that 12 weeks of administration of ixekizumab with drugs metabolized by CYP3A4 (i.e., midazolam), CYP2C9 (i.e., warfarin), CYP2C19 (i.e., omeprazole), CYP1A2 (i.e., caffeine) or CYP2D6 (i.e., dextromethorphan) does not have a clinically significant impact on the pharmacokinetics of these drugs. 
Rezultati študije o medsebojnem delovanju zdravil pri bolnikih z zmerno do hudo psoriazo so pokazali, da 12 tednov dajanja iksekizumaba skupaj z drugimi zdravili, ki se presnavljajo prek CYP3A4 (tj. midazolam), CYP2C9 (tj. varfarin), CYP2C19 (tj. omeprazol), CYP1A2 (tj. kofein) ali
The efficacy and safety of Taltz was demonstrated regardless of age, gender, race, body weight, PASI baseline severity, plaques location, concurrent psoriatic arthritis, and previous treatment with a biologic. 
Učinkovitost in varnost zdravila Taltz sta bili dokazani ne glede na starost, spol, raso, telesno maso, resnost izhodiščne ocene PASI, mesto plakov, sočasnost psoriatičnega artritisa in predhodno zdravljenje z biološkim zdravilom.
In SPIRIT-P1, efficacy was maintained up to Week 52 as assessed by ACR 20/50/70, MDA, enthesitis resolution, dactylitis resolution, and PASI 75/90/100 response rates. 
V študiji SPIRIT-P1 se je učinkovitost ohranila do 52. tedna, ocenjeno po merilih ACR 20/50/70, minimalne aktivnosti bolezni (Minimal Disease Activity - MDA), odpravljanju entezitisa, odpravljanju daktilitisa in stopnjah odziva PASI 75/90/100.
A total of 3,119 patients were evaluated (1,161 patients on 80 mg every 4 weeks (Q4W), 1,167 patients on 80 mg every 2 weeks (Q2W) and 791 patients on placebo). 
Skupno so ocenili 3119 bolnikov (1161 bolnikov, ki so prejemali odmerek 80 mg vsake 4 tedne (Q4W), 1167 bolnikov, ki so prejemali odmerek 80 mg vsaka 2 tedna (Q2W) in 791 bolnikov, ki so prejemali placebo).
ADRs from clinical studies and postmarketing reports (Table 1) are listed by MedDRA system organ class. 
Tabelarični prikaz neželenih učinkov Neželeni učinki zdravila iz kliničnih študij in poročil iz obdobja trženja zdravila (Preglednica 1) so navedeni po organskih sistemih klasifikacije MedDRA.
The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) at Weeks 2, 4, 6, 8, 10, and 12, then maintenance dosing of 80 mg (one injection) every 4 weeks. 
Priporočeni odmerek je 160 mg s subkutano injekcijo (dve injekciji po 80 mg) v tednu 0, ki mu sledi 80 mg (ena injekcija) v tednih 2, 4, 6, 8, 10 in 12, nato pa vzdrževalno odmerjanje 80 mg (ena injekcija) vsake 4 tedne.
Serious infections were reported in 1.6 % of patients treated with Taltz (1.5 per 100 patient years). 
Pri 1,6 % bolnikov, zdravljenih z zdravilom Taltz (1,5 na 100 bolnik-let), so poročali o resnih okužbah.
A. Do not touch the needle or replace the base cap. 
O: Ne dotikajte se igle in ne nameščajte pokrovčka podnožja nazaj.
A total of 678 patients were evaluated (229 patients on 80 mg every 4 weeks (Q4W), 225 patients on 80 mg every 2 weeks (Q2W) and 224 patients on placebo). 
Skupno so ocenili 678 bolnikov (229 bolnikov, ki so prejemali odmerek 80 mg vsake 4 tedne (Q4W), 225 bolnikov, ki so prejemali odmerek 80 mg vsaka 2 tedna (Q2W) in 224 bolnikov, ki so prejemali placebo).
Injection site reactionsf a Placebo-controlled clinical studies (phase III) in moderate to severe plaque psoriasis patients exposed to ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W or placebo for up to 12 weeks of treatment duration, or in active psoriatic arthritis patients exposed to ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W or placebo for up to 24 weeks of treatment duration. 
Zelo pogosti reakcije na mestu injiciranjaf a S placebom nadzorovane klinične študije (3. faze) pri bolnikih z zmerno do hudo psoriazo s plaki, ki so bili izpostavljeni iksekizumabu 80 mg Q2W, iksekizumabu 80 mg Q4W ali placebu v obdobju zdravljenja do 12. tedna, ali pri bolnikih z aktivnim psoriatičnim artritisom, ki so bili izpostavljeni iksekizumabu 80 mg Q2W, iksekizumabu 80 mg Q4W ali placebu v obdobju zdravljenja do 24. tedna.
Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. 
Zdravilo Taltz je indicirano za zdravljenje zmerne do hude psoriaze s plaki pri odraslih, ki so primerni za sistemsko zdravljenje.
- The active substance is ixekizumab. 
- Učinkovina je iksekizumab.
The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) every 4 weeks thereafter. 
Priporočeni odmerek je 160 mg, dan s subkutano injekcijo (dve injekciji po 80 mg) v tednu 0, ki mu sledi odmerek 80 mg (ena injekcija) vsake 4 tedne po tem.
Significant improvements in itch severity were seen at Week 1 in patients treated with Taltz. 
Pomembno zmanjšanje v jakosti srbenja so opazili v 1. tednu pri bolnikih, zdravljenih z zdravilom Taltz.
You should not be given certain types of vaccines while using Taltz. 
Med uporabo zdravila Taltz vam ne smejo dati nekaterih cepiv.
Contact your doctor, pharmacist or nurse. 
Obvestite zdravnika, farmacevta ali medicinsko sestro.
In psoriatic arthritis, two placebo-controlled phase III studies were integrated to evaluate the safety of Taltz in comparison to placebo up to 24 weeks after treatment initiation. 
Za psoriatični artritis sta bili dve študiji 3. faze, nadzorovani s placebom, vključeni za oceno varnosti zdravila Taltz v primerjavi s placebom do 24 tednov po uvedbi zdravljenja.
• It is past the expiry date. 
• Rok uporabnosti je pretečen.
1 pre-filled syringe of 1 ml solution 2 pre-filled syringes of 1 ml solution 3 pre-filled syringes of 1 ml solution 
1 napolnjeni injekcijski peresnik z 1 ml raztopine 2 napolnjena injekcijska peresnika z 1 ml raztopine 3 napolnjeni injekcijski peresniki z 1 ml raztopine
A higher incidence of postnatal mortality occurred in the offspring of monkeys given ixekizumab compared to concurrent controls. 
Pri potomcih opic, ki so prejemale iksekizumab, so opazili višjo incidenco poporodnega pogina, v primerjavi s sočasnimi kontrolami.
A total of 7,339 patients have been treated with Taltz in blinded and open-label clinical studies in plaque psoriasis, psoriatic arthritis, and other autoimmune conditions. 
V slepih in odprtih kliničnih študijah so z zdravilom Taltz zdravili skupno 7339 bolnikov, ki so imeli psoriazo s plaki, psoriatični artritis in druge avtoimune bolezni.
- The other ingredients are sodium citrate; citric acid, anhydrous; sodium chloride; polysorbate 80; water for injections. 
- Druge sestavine zdravila so natrijev citrat, brezvodna citronska kislina, natrijev klorid, polisorbat 80, voda za injekcije.
(nasopharyngitis). 
(subkutano injiciranje).
As a direct consequence treatment with ixekizumab reduces erythema, induration and desquamation present in plaque psoriasis lesions. 
Na ta način zdravljenje z iksekizumabom zmanjšuje eritem, debelino epidermija in luščenje, ki so prisotni pri lezijah psoriaze s plaki.
It is preferable to avoid the use of Taltz in pregnancy. 
Med nosečnostjo se je bolje izogibati uporabi zdravila Taltz.
- low blood platelet count (thrombocytopenia). 
- nizko število krvnih ploščic (trombocitopenija),
Excipients: sodium citrate; citric acid, anhydrous; sodium chloride; polysorbate 80; water for injections. 
Pomožne snovi: natrijev citrat, brezvodna citronska kislina, natrijev klorid, polisorbat 80, voda za injekcije.
TALTZ Placebo Difference from placebo (95% CI) 
TALTZ Placebo Razlika od placeba (95-odstotni interval zaupanja)
Commonly asked questions Q. What if I see air bubbles in my syringe? 
V: Kaj moram narediti, če v svoji brizgi opazim zračne mehurčke?
Abbreviations: ADA = adalimumab; CI = confidence interval; Q4W = Taltz 80 mg every 4 weeks; Q2W = Taltz 80 mg every 2 weeks; LSM = least squares mean; N = number of patients in the analysis population; PBO = placebo; SE = standard error; SD = standard deviation. 
Okrajšave: ADA = adalimumab; IZ = interval zaupanja; Q4W = Taltz 80 mg vsake 4 tedne; Q2W = Taltz 80 mg vsaka 2 tedna; LSM = povprečna vrednost najmanjših kvadratov; N = število bolnikov v analizirani populaciji; PBO = placebo; SE = standardna napaka; SD = standardni odklon.
Do not use this medicine if you notice that the syringe is damaged, or the medicine is cloudy, distinctly brown, or has particles in it. 
Ne uporabljajte tega zdravila, če opazite, da je brizga poškodovana, ali da je zdravilo motno, izrazito rjave barve ali da v njem plavajo delci.
Concomitant cDMARDs included MTX, leflunomide and sulfasalazine. 
MTX, leflunomid in sulfasalazin.
Renal or hepatic impairment Taltz has not been studied in these patient populations. 
Zdravila Taltz v tej skupini bolnikov niso proučevali.
Gently remove the needle from your skin. 
Nežno izvlecite iglo iz kože.
In patients with pre-existing dactylitis or enthesitis, treatment with Taltz Q4W resulted in improvement in dactylitis and enthesitis at Week 24 compared to placebo (resolution: 78% vs. 24%; p<0.001, and 39% vs. 21%; p<0.01, respectively). 
Pri bolnikih z že obstoječim daktilitisom ali entezitisom je zdravljenje z režimom Taltz Q4W v primerjavi s placebom povzročilo izboljšanje daktilitisa in entezitisa v 24. tednu (odprava: 78 % v primerjavi s 24 %; p < 0,001 in 39 % v primerjavi z 21 %; p < 0,01).
points at week 12 (84.6% for Taltz Q2W, 79.2% for Taltz Q4W and 16.5% for placebo) and the benefit was sustained over time up to Week 60 in patients treated with Taltz who were sPGA (0 or 1) 
12. tednu (84,6 % za zdravilo Taltz Q2W, 79,2 % za zdravilo Taltz Q4W in 16,5% za placebo), učinek pa se je ohranil daljši čas, do 60. tedna pri bolnikih, zdravljenih z zdravilom Taltz, ki do imeli v 12.
Consider anti-TB therapy prior to initiation of Taltz in patients with latent TB. 
Pri bolnikih z latentno tuberkulozo je treba pred začetkom zdravljenja z zdravilom Taltz razmisliti o zdravljenju proti tuberkulozi.
(Based on adverse reactions data from 4,204 patients with moderate to severe plaque psoriasis [4,729.7 patient years] and 1,117 patients with active psoriatic arthritis [1,050.6 patient years] who have received at least 1 dose of ixekizumab.) 
Opis izbranih neželenih učinkov (Na podlagi podatkov o neželenih učinkih pri 4204 bolnikih z zmerno do hudo psoriazo s plaki [4729,7 bolnik-let] in pri 1117 bolnikih z aktivnim psoriatičnim artritisom [1050,6 bolnik-let], ki so prejeli najmanj 1 odmerek iksekizumaba.)
The proportion of patients achieving a PASI 75, PASI 90, and PASI 100 response at Week 24 was greater with Taltz Q4W compared to placebo (p<0.001). 
PASI 75, PASI 90 in PASI 100 v 24. tednu, je bil večji pri režimu Taltz Q4W v primerjavi s placebom (p<0,001).
- Eczema - Rash - Rapid swelling of the tissues of the neck, face, mouth or throat (angioedema) 
- hitro otekanje tkiv vratu, obraza, ust ali grla (angioedem).
Over 58.9% and 22.3% of the psoriatic arthritis patients had enthesitis and dactylitis at baseline, respectively. 
V izhodišču je imelo več kot 58,9 % bolnikov s psoriatičnim artritisom entezitis, 22,3 % bolnikov s psoriatičnim artritisom pa daktilitis.
Do not use this medicine if you notice that the pen is damaged, or the medicine is cloudy, distinctly brown, or has particles in it. 
Ne uporabljajte tega zdravila, če opazite, da je peresnik poškodovan, ali da je zdravilo motno, izrazito rjave barve ali da v njem plavajo delci.
Taltz should not be used if particles appear or if the solution is cloudy and/or distinctly brown. 
Zdravila Taltz ne smete uporabljati, če so v raztopini vidni delci ali če je raztopina motna in/ali izrazito rjave barve.
In plaque psoriasis, three placebo-controlled phase III studies were integrated to evaluate the safety of Taltz in comparison to placebo up to 12 weeks after treatment initiation. 
Za psoriazo s plaki so bile tri študije 3. faze, nadzorovane s placebom, vključene za oceno varnosti zdravila Taltz v primerjavi s placebom do 12 tednov po uvedbi zdravljenja.
In Psoriatic Arthritis Study 1 (SPIRIT-P1), patients naive to biologic therapy with active psoriatic arthritis were randomised to subcutaneous injections of placebo, adalimumab 40 mg once every 2 weeks (active control reference arm), Taltz 80 mg once every 2 weeks (Q2W), or 80 mg once every 4 weeks (Q4W). 
V študiji psoriatičnega artritisa 1 (SPIRIT-P1) so bili bolniki z aktivnim psoriatičnim artritisom, ki še niso bili zdravljeni z biološkimi zdravili, randomizirani za prejemanje subkutanih injekcij placeba, adalimumaba 40 mg enkrat na vsaka 2 tedna (referenčna skupina z aktivno kontrolo), zdravila Taltz 80 mg enkrat na vsaka 2 tedna (Q2W) ali 80 mg enkrat na vsake 4 tedne (Q4W).
significantly greater proportion of patients treated with Taltz achieved a reduction of Itch NRS ≥ 4 
Bistveno večji delež bolnikov, zdravljenih z zdravilom Taltz, je dosegel znižanje ocene na lestvici srbenja NRS ≥ 4 točk v
“1” (rarely limited) a Abbreviations: NRI = Non-Responder Imputation; sPGA = static Physician Global Assessment; GPSS = Genital Psoriasis Symptom Scale; SFQ = Sexual Frequency Questionnaire; DLQI = Dermatology Quality of Life Index; b Total DLQI score of 0,1 indicates skin condition has no effect at all on patient's life. 
Postavka 2 vprašalnika SFQ »0« (nikoli omejeno) ali »1« (redko omejeno) aOkrajšave: NRI = imputacija manjkajočih podatkov za bolnike, ki se niso odzvali (Non-Responder Imputation); sPGA = statična globalna ocena zdravnika (static Physician Global Assessment); GPSS = lestvica simptomov genitalne psoriaze (Genital Psoriasis Symptom Scale); SFQ = vprašalnik o pogostnosti spolne aktivnosti (Sexual Frequency Questionnaire); DLQI = dermatološki indeks kakovosti življenja (Dermatology Quality of Life Index); bSkupna ocena DLQI 0,1 kaže na stanje kože, ki nima nobenega vpliva na bolnikovo življenje.
Onset of response was superior on PASI 75 as early as week 2 (p < 0.001) and on PASI 90 and PASI 100 by week 4 (p < 0.001). 
Hitrost odziva za opazovani dogodek PASI 75 je bila superiorna že v 2. tednu (p < 0,001) in za opazovani dogodek PASI 90 ter PASI 100 v 4. tednu
After proper training in subcutaneous injection technique, patients may self-inject Taltz if a healthcare professional determines that it is appropriate. 
Po ustreznem usposabljanju o subkutanem injiciranju si lahko bolniki sami injicirajo zdravilo
Q. What if I unlocked the pre-filled pen and pressed the green injection button before I twisted off the base cap? 
V: Kaj če odklenem napolnjeni injekcijski peresnik in pritisnem zeleni gumb za injiciranje,
- Cold sores of mouth, skin and mucous membranes (herpes simplex, mucocutaneous) 
- herpes na ustih, koži in sluznicah (mukokutani herpes simpleks).
Efficacy in Non-Responders to Etanercept: For patients identified as an sPGA (0,1) non-responder to etanercept at Week 12 in UNCOVER-2 (N = 200) and who were switched to Taltz 80 mg Q4W after a 4 week washout period, 73 % and 83.5 % of patients were able to achieve sPGA (0,1) and PASI 75, respectively, after 12 weeks of being treated with Taltz. 
Učinkovitost pri bolnikih, ki se niso odzvali na etanercept: Pri bolnikih, ki se niso odzvali na etanercept, so imeli oceno sPGA (0,1) v 12. tednu v študiji UNCOVER-2 (N = 200) in so prešli na zdravljenje z zdravilom Taltz 80 mg Q4W po 4-tedenskem obdobju izpiranja, je 73 % in 83,5 % bolnikov doseglo oceno sPGA (0,1) oziroma PASI 75, po 12. tednih zdravljenja z zdravilom Taltz.
For sPGA (0,1) responders at Week 12 re-randomised to treatment withdrawal (i.e., placebo), the median time to relapse (sPGA ≥ 3) was 164 days in integrated UNCOVER-1 and UNCOVER-2 studies. 
Bolniki, ki so se odzvali z oceno sPGA (0,1) v 12. tednu in so bili znova randomizirani v skupino brez zdravljenja (tj. placebo), je bil mediani čas do ponovnega pojava znakov (sPGA ≥ 3) 164 dni v integriranih študijah UNCOVER-1 in UNCOVER-2.
The frequency of neutropenia and thrombocytopenia in psoriatic arthritis clinical studies is similar to that observed in the plaque psoriasis studies. 
Pogostnost nevtropenije in trombocitopenije v kliničnih študijah psoriatičnega artritisa je podobna pogostnosti, ki so jo opazili v študijah psoriaze s plaki.
Q. What if there is a drop of liquid on the tip of the needle when I remove the base cap? 
V: Kaj če opazim kapljico tekočine na konici igle, ko odstranim pokrovček podnožja?
The pharmacokinetic properties of Taltz observed in psoriatic arthritis patients were similar to those displayed in plaque psoriasis patients. 
Psoriatični artritis Farmakokinetične lastnosti zdravila Taltz pri bolnikih s psoriatičnim artritisom so bile podobne tistim pri bolnikih s psoriazo s plaki.
• If you do not have a sharps container, ask your doctor, pharmacist or nurse about where you can get one. 
• Če nimate zbiralnika za ostre predmete, se pri zdravniku, farmacevtu ali medicinski sestri pozanimajte, kje ga lahko dobite.
Taltz is a solution in a clear glass syringe. 
Zdravilo Taltz je raztopina v brizgi iz prozornega stekla.
The safety profile observed in patients with psoriatic arthritis treated with Taltz is consistent with the safety profile in plaque psoriasis with the exception of the frequencies of the adverse reactions of influenza and conjunctivitis which were common in patients with psoriatic arthritis. 
Varnostni profil, ki so ga opazili pri bolnikih s psoriatičnim artritisom, zdravljenih z zdravilom Taltz, je skladen z varnostnim profilom pri psoriazi s plaki, z izjemo pogostnosti neželenih učinkov gripe in konjunktivitisa, ki sta bila pogosta neželena učinka pri bolnikih s psoriatičnim artritisom.
sPGA of “0” (clear) or “1” (minimal) 
sPGA "0" (čisto) ali "1" (minimalno)
Leave the base cap on until you are ready to inject. 
Pokrovčka ohišja ne snemajte, dokler niste pripravljeni na injiciranje.
Oropharyngeal pain 
Navojni pokrovček ohišja
Let the injection site dry naturally before you inject your medicine. 
Injekcijsko mesto se mora pred injiciranjem zdravila posušiti na zraku.
- signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections 
- izcedek iz oči s srbenjem, pordelostjo in otekanjem (konjunktivitis), - znaki nizkih ravni belih krvničk, kot so povišana telesna temperatura, boleče grlo ali razjede v ustih zaradi okužb (nevtropenija),